Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

±¤¹üÀ§ÇÑ °£ ħ½ÀÀ» º¸ÀÌ´Â °£¼¼Æ÷¾Ï¿¡¼­ÀÇ °£µ¿¸Æ³» Cis-Diamminedichloroplatinum ÁÖÀÔ ¿ä¹ý¿¡ ÀÇÇÑ Ä¡·á Intra-Arterial Cis-Diamminedichloroplatinum Infusion Treatment for Widespread Hepatocellular Carcinoma

´ëÇѹæ»ç¼±ÀÇÇÐȸÁö 1997³â 37±Ç 6È£ p.1025 ~ 1031
¼Ò¼Ó »ó¼¼Á¤º¸
¹Ú¼ºÀÏ/Sung Il Park ¾çÈñö/À̵µ¿¬/½É¿ë¿î/±è»óÈì/±è¸íÁø/ÀÌÁ¾ÅÂ/À¯Çü½Ä/Hee Chul Yang/Do Yon Lee/Yong Woon Shim/Sang Heum Kim/Myeong Jin Kim/Jong Tae Lee/Hyung Sik Yoo

Abstract

¸ñ Àû : °£ ³»¿¡ ±¤¹üÀ§ÇÑ Ä§¹üÀ» º¸ÀÌ´Â ¿ø¹ß¼º °£¼¼Æ÷¾Ï¿¡¼­ÀÇ °£µ¿¸Æ ³»
Cis-Diamminedichloroplatinum (C-DDP) ÁÖÀÔ¿ä¹ý¿¡ ÀÇÇÑ Ä¡·á È¿°ú¸¦ ¾Ë¾Æº¸°íÀÚ ÇÏ¿´´Ù.
´ë»ó ¹× ¹æ¹ý : 1994³â 7¿ù 1996³â 6¿ù±îÁö °£ ³»¿¡ ±¤¹üÀ§ÇÑ Ä§¹üÀ¸·Î °£µ¿¸Æ »öÀü¼úÀ»
½ÃÇàÇÏÁö ¾Ê°í °£µ¿¸Æ ³» C-DDP ´Üµ¶ ÁÖÀÔ¿ä¹ý¸¸À¸·Î Ä¡·áÇÏ¿´´ø ¿ø¹ß¼º °£¼¼Æ÷¾Ï 22¿¹¸¦
ÈÄÇâÀûÀ¸·Î ºÐ¼®ÇÏ¿´´Ù. ´ë»ó ¾ÏÀº °£ÀÇ ¾çÃø ¿±À» ħ¹üÇÑ ¿¹°¡ 10¿¹, ¹®¸Æ Æó¼â 14¿¹, µ¿¹®
¸Æ·ù 9¿¹, µ¿Á¤¸Æ·ù 2¿¹¿´´Ù. Ä¡·á´Â °íÀ¯ °£µ¿¸Æ¿¡¼­ üǥ¸éÀû´ç 100§·ÀÇ C-DDP¸¦ 3³»Áö
4ÁÖ °£°ÝÀ¸·Î ¹Ýº¹ÇÏ¿© ÁÖÀÔÇÏ¿´°í 65ȸ¸¦ ½ÃÇàÇÏ¿´´Ù. ±¹Á¦º¸°Ç±â±¸ ±âÁØ¿¡ µû¶ó ¿ÏÀü °ü
ÇØ, ºÎºÐ °üÇØ, ¾ÈÁ¤¼º º´º¯ ¹× ÁøÇ༺ º´º¯À¸·Î ±¸ºÐÇÏ¿© Ä¡·á ¹ÝÀÀÀ» Æò°¡ÇÏ¿´°í 6°³¿ù ¹×
1³â »ýÁ¸À²À» ±¸ÇÏ¿´À¸¸ç Ä¡·áÀÇ ºÎÀÛ¿ëÀ» ¾Ë¾Æº¸¾Ò´Ù.
°á °ú : ´ë»ó ȯÀÚ 22¿¹¿¡¼­ ¿ÏÀü°üÇظ¦ º¸ÀÎ ¿¹°¡ 1¿¹(4.5%), ºÎºÐ°üÇظ¦ º¸ÀÎ ¿¹°¡ 3¿¹
(13.6%)¿´°í Ä¡·á¿¡ ¹ÝÀÀÀ» º¸ÀÌÁö ¾ÊÀº ¿¹°¡ 18¿¹¿´´Ù. 6°³¿ù »ýÁ¸À²Àº 59.1%¿´°í 1³â »ý
Á¸À²Àº 32.1%¿´´Ù. ºÎÀÛ¿ëÀº ¿À½É ¹× ±¸Åä(59.2%), º¹Åë(9.2%), ¹ß¿­(8.0%), ±Þ¼º ½ÅºÎÀü
(2.3%) ¹× °£¼º È¥¼ö(1.1%)°¡ ÀÖ¾úÀ¸³ª ÀϽÃÀûÀ̾ú°í °¡¿ªÀûÀ̾ú´Ù.
°á ·Ð : °£µ¿¸Æ³» C-DDP ÁÖÀÔ¿ä¹øÀº Ä¡·á È¿°ú´Â Á¦ÇÑÀûÀ̳ª ºÎÀÛ¿ëÀÌ ÀûÀ¸¹Ç·Î °£µ¿¸Æ
»öÀü¼ú·Î Ä¡·áÇϱ⠾î·Á¿î ±¤¹üÀ§ÇÑ °£ ħ½ÀÀ» º¸ÀÌ´Â ¿ø¹ß¼º °£ ¼¼Æ÷¾Ï¿¡¼­ ¼±ÅÃÇÒ ¼ö ÀÖ
´Â ÁÁÀº ´ë¾ÈÀûÀÎ Ä¡·á ¹æ¹ýÀ¸·Î »ý°¢µÈ´Ù.

Purpose : To evaluate the therapeutic efficacy of intra-arterial infusion of
Cis-Diamminedichloroplatinum(C-DDP) for the treatment of hepatocellular carcinomas
with widespread involvement.
Materials and Methods : We retrospectively analyzed 22 patients who between July
1994 and June 1996 had undergone intra-arterial c-DDP infusion therapy for the
treatment of hepatocelluar carcinomas with widespread involvement. The hepatomas
involved both lobes in ten, portal venous obstruction in fourteen, arterio-portal shunts in
nine, and arterio-venous shunts in two. Proper hepatic artery was selected for infusion
of 100§·/BSA of C-DDP. The same procedure was repeated every 3 to 4 weeks, and
the total number of infusions was 65. On the basis of WHO criteria, response was
classified as complete remission, partial remission, stable, or progression of the disease.
Six-month and one-year survival rates were estimated, and adverse reactions were
evaluated.
Results : Complete remission was noted in one patient (4.5%) and partial remission in
three(13.6%), while 18 showed no response or progression after treatment. The six
month survival rate was 59.1%, and the one-year survival rate was 32.1%. Adverse
reactions included nausea/vomition(59.8%), abdominal pain(9.2%), fever(8.0%), acute renal
failure (2.3%) and hepatic encephalopathy (1.1%). These adverse reactions were,
however, transient and reversible.
Conclusion : Although the response rate is not high, intra-arterial C-DDP infusion
therapy can be used as an alternative treatment for hepatocellular carcinomas with
widespread involvement ; adverse reactions are tolerable.

Å°¿öµå

Liver neoplasms; chemotherapeutic infusion; Liver neoplasms; therapy;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS